Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis

Abstract

The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04–2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30–3.22), colorectal cancer (HR=1.40, 95% CI=1.04–1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12–2.89), for Europeans (HR=1.98, 95% CI=1.44–2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10–2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25–2.77) and poor differentiation (OR=1.88, 95% CI=1.14–3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.

Keywords

Sox2 / digestive tract cancer / prognosis / meta-analysis

References

[1] BrayF, JemalA, GreyN, et al. . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol, 2012, 13(8): 790-801 PMID: 22658655

[2] SiegelR, MaJ, ZouZ, et al. . Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29 PMID: 24399786

[3] PennathurA, GibsonMK, JobeBA, et al. . Oesophageal carcinoma. Lancet, 2013, 381(9864): 400-412 PMID: 23374478

[4] DeSantisCE, LinCC, MariottoAB, et al. . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014, 64(4): 252-271 PMID: 24890451

[5] RassouliFB, MatinMM, SaeinasabM. Cancer stem cells in human digestive tract malignancies. Tumour Biol, 2016, 37(1): 7-21 PMID: 26446457

[6] StevanovicM, ZuffardiO, CollignonJ, et al. . The cDNA sequence and chromosomal location of the human SOX2 gene. Mamm Genome, 1994, 5(10): 640-642 PMID: 7849401

[7] TakahashiK, YamanakaS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4): 663-676 PMID: 16904174

[8] MasuiS, NakatakeY, ToyookaY, et al. . Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol, 2007, 9(6): 625-635 PMID: 17515932

[9] SarkarA, HochedlingerK. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell, 2013, 12(1): 15-30 PMID: 23290134 PMCID: 3608206

[10] BassAJ, WatanabeH, MermelCH, et al. . SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet, 2009, 41(11): 1238-1242 PMID: 19801978 PMCID: 2783775

[11] HussenetT, DaliS, ExingerJ, et al. . SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PloS one, 2010, 5(1): e8960 PMID: 20126410 PMCID: 2813300

[12] FreierK, KnoepfleK, FlechtenmacherC, et al. . Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma. Genes Chromosomes Cancer, 2010, 49(1): 9-16 PMID: 19787784

[13] StolzenburgS, RotsMG, BeltranAS, et al. . Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res, 2012, 40(14): 6725-6740 PMID: 22561374 PMCID: 3413152

[14] LengerkeC, FehmT, KurthR, et al. . Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC cancer, 2011, 28(11): 42

[15] LouX, HanX, JinC, et al. . SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention. OMICS, 2013, 17(10): 510-518 PMID: 23895273 PMCID: 3783972

[16] SunC, SunL, LiY, et al. . Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol, 2013, 30(2): 503 PMID: 23430442

[17] ChenY, HuangY, HuangY, et al. . The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PloS One, 2013, 8(8): e71140 PMID: 23990933 PMCID: 3747201

[18] CamiloV, BarrosR, CelestinoR, et al. . Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC cancer, 2014, 9(14): 753

[19] SaigusaS, MohriY, OhiM, et al. . Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol Rep, 2011, 26(5): 1069-1074 PMID: 21811761

[20] MatsuokaJ, YashiroM, SakuraiK, et al. . Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res, 2012, 174(1): 130-135 PMID: 21227461

[21] ShimadaY, OkumuraT, SekineS, et al. . Expression analysis of iPS cell-inductive genes in esophageal squamous cell carcinoma by tissue microarray. Anticancer Res, 2012, 32(12): 5507-5514 PMID: 23225459

[22] ZhangX, YuH, YangY, et al. . SOX2 in gastric carcinoma, but not Hath1, is related to patients' clinicopathological features and prognosis. J Gastrointest Surg, 2010, 14(8): 1220-1226 PMID: 20532662

[23] StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605 PMID: 20652370

[24] HoningJ, PavlovKV, MeijerC, et al. . Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients. Ann Surg Oncol, 2014, 21(4): S657-S664 PMID: 24833101

[25] LeeHJ, EomDW, KangGH, et al. . Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells. Mod Pathol, 2013, 26(8): 1123-1131 PMID: 23060121

[26] LundbergI L, BurstromA, EdinS, et al. . SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer. PloS one, 2014, 9(7): e101957 PMID: 25010701 PMCID: 4092103

[27] ChenY, LiD, WangD, et al. . Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells. J Cell Biochem, 2012, 113(12): 3643-3652 PMID: 22711554

[28] ChenT, YangK, YuJ, et al. . Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res, 2012, 22(1): 248-258 PMID: 21727908

[29] TodaroM, FrancipaneMG, MedemaJP, et al. . Colon cancer stem cells: promise of targeted therapy. Gastroenterology, 2010, 138(6): 2151-2162 PMID: 20420952

[30] GenY, YasuiK, ZenY, et al. . SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet, 2010, 202(2): 82-93 PMID: 20875870

[31] SaikiY, IshimaruS, MimoriK, et al. . Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol, 2009, 16(9): 2638-2644 PMID: 19554373

[32] NeumannJ, BahrF, HorstD, et al. . SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC cancer, 2011, 14(11): 518

[33] UozakiH, BaruaRR, MinhuaS, et al. . Transcriptional factor typing with SOX2, HNF4aP1, and CDX2 closely relates to tumor invasion and Epstein-Barr virus status in gastric cancer. Int J Clin Exp Pathol, 2011, 4(3): 230-240 PMID: 21487519 PMCID: 3071656

[34] WangQ, HeW, LuC, et al. . Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res, 2009, 29(4): 1233-1241 PMID: 19414369

[35] LiXL, EishiY, BaiYQ, et al. . Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Cncol, 2004, 24(2): 257-263